R1 RCM (RCM) Receives a Buy from RBC Capital

RBC Capital analyst Sean Dodge maintained a Buy rating on R1 RCM (RCMResearch Report) on June 27 and set a price target of $35.00. The company’s shares closed last Tuesday at $21.22.

According to, Dodge is a 1-star analyst with an average return of -1.9% and a 45.6% success rate. Dodge covers the Technology sector, focusing on stocks such as Tabula Rasa HealthCare, NextGen Healthcare, and Thorne HealthTech.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for R1 RCM with a $32.50 average price target, implying a 47.6% upside from current levels. In a report issued on June 24, Deutsche Bank also maintained a Buy rating on the stock.

See the top stocks recommended by analysts >>

The company has a one-year high of $27.86 and a one-year low of $18.71. Currently, R1 RCM has an average volume of 1.25M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Chicago, IL.

Read More on RCM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed